TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05893277

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) and Behavioral Couples Therapy (BCT)
Description: Four Motivational Interviewing sessions with the husband (wife joins for last MI session) to reduce alcohol use dependency, followed by six Behavioral Couples Therapy session with the husband and wife together to improve their relation and communication and reduce intimate partner violence. Session 1: couple establishes daily trust contract and discusses strategies to cope with reduced alcohol use. Session 2: couple revisits these coping skills and builds on additional strategies, as necessary. Session 3: they shift to improving the relationship and communication. Session 4: activity to promote caring behavior between partners. Session 5: couple reviews communication strategies learned previously, learn active listening and address any ongoing communication challenges. Session 6: review session and plans to address challenges to create long-term change.
Study: NCT04787497

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Phenolic Extra Virgin Olive Oil
Description: Participants will be assigned in two groups: the Experimental Group (N= 20) will be receiving 50ml of freshly, cold-pressed, oleocanthal-rich Extra Virgin Olive Oil (EVOO) alongside their prescribed medical treatment, whereas the Control Group (N = 20) will be receiving their medical treatment as usual. The Experimental Group will be receiving the complementary treatment on a daily basis for 12 months and all participants will undergo a neuropsychological assessment at baseline, 6 months and 12 months +/- 7 days after their first assessment or beginning of treatment.
Study: NCT06383520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-aGPC3-scFv/Fab
Description: For pharmacokinetics, healthy volunteer underwent PET imaging targeting GPC3. Blood samples were collected at 25 min, 55 min, and 115 min after imaging agent injection, and urine specimens were collected at 28 min, 58 min, and 118 min after injection to measure radioactivity in blood and urine. PET/MR scans were performed at 30-50 min, 60-80 min, and 120-140 min after injection to understand absorption, distribution, and metabolism.~For Cancer patients, subjects should have targeting GPC3 and 18F-FDG PET scans two days apart.~Blood tests, liver and kidney function, tumor markers (AFP, etc.), and other biochemical markers must be performed one week prior to and after imaging.~Tumor biopsies or surgical specimens should be evaluated histopathologically and immunostained for biomarkers associated with angiogenesis.
Study: NCT04748796

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: echocardiography
Description: Full echocardiography will be performed at baseline and during the follow-up at H1, H3, H6 and H12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Landiolol
Description: Patients randomized to the experimental group will be treated according to the standard of care plus for 2 days with landiolol IV started at a dose of 1 microgram/kg/min and progressively increased every 10 minutes to a maximum of 40 micrograms/kg/min.
Study: NCT05224336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: 25mg oral psilocybin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Niacin
Description: 100mg oral niacin
Study: NCT04483076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA \> 1.5 m2. Day 15 to day 21 is the rest period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: The preoperative SOX chemotherapy consists of three-week cycles of intravenously administered oxaliplatin 130 mg/m2 on day 1 and orally administered S-1 40-60 mg twice a day (BID) on day 1 to 14. The dose of S-1 depends on body surface area (BSA): 40mg BID for BSA \< 1.25 m2; 50mg BID for 1.25 m2 \< BSA \<1.5 m2; 60mg BID for BSA \> 1.5 m2. Day 15 to day 21 is the rest period.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastrectomy
Description: Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastrectomy
Description: Surgery is planned 3-4 weeks after the last cycle of chemotherapy. A standard D2 radical laparoscopic gastrectomy is recommended. The extent of gastric resection and lymphadenectomy were performed as per the treatment guidelines. Reconstruction after gastrectomy was decided by the surgeon. All operations are performed by well trained and experienced surgical team to guarantee the quality of surgery, including harvesting more than 16 lymph nodes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic exploration
Description: Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic exploration
Description: Laparoscopic exploration is to detect occult peritoneal metastases and inspect the primary lesion, liver, diaphragm, pelvic organs, bowel and omentum according to the standard acquirements reported before. Patients with any patterns of distant metastases, suggestive of distant metastasis (M1), will be excluded from the trial.
Study: NCT05252052

Intervention type: OTHER
Intervention: Interviews/Surveys
Description: This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti

Intervention type: OTHER
Intervention: Interviews/Surveys
Description: This is a cross sectional survey and interviews of adolescents 14- 18 years old and HCPs living in rural Haiti
Study: NCT04719078

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI of the chest
Description: The study participants will obtain a MRI of the thorax with one of the institutions MR machines (Philips Achieva 1.5T, GE Discovery 3T, MRI Siemens Skyra 3T, and GE SIGNA Artist 1.5T). The study participant will be asked to lie in the MR scanner for about 30 minutes while the images will be acquired. The image acquisition with the above-mentioned MR machines is authorised in Switzerland and the application is done according to the product information.
Study: NCT04600700

Intervention type: DEVICE
Intervention: Clinical Decision support system (CDSS) for inotrope weaning
Description: A Clinical Decision Support System informed by 6-hour rolling average IDO2, will be utilized during the intervention phase of the study. The CDSS tool will be introduced in a stepped-wedge pattern. Randomization will occur by center, with time of introduction being staggered, with each center ultimately receiving the CDSS intervention. Teams in the CICU make rounds twice per day. During each of the rounds (AM and PM), the team will refer to the CDSS and the 6-hour average IDO2 (as reported on the T3 platform at the bedside computer). The clinical team will consider the CDSS in decision making around inotrope weans. If the decision is made to not utilize IDO2, the bedside clinician will complete a brief survey with rationale.
Study: NCT05768256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive-behavioral Therapy for Distress
Description: Mindfulness-based cognitive-behavioral therapy, MBCT, is a modified form of cognitive-behavioral therapy that incorporates mindfulness practices that include present moment awareness, meditation, and breathing exercises. Advanced cancer patients will participate in the study until the end of the study (Feb 2024). After registering for the study, the study subjects receive mindfulness-based cognitive behavioral therapy once a week for eight weeks.
Study: NCT05730270

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction program 1
Description: Participants will receive daily online lessons

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress reduction program 2
Description: Participants will receive daily online lessons
Study: NCT05020288

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: Orelabrutinib 50mg po qd, every four weeks for one cycle. It will be given three cycles.
Study: NCT05699135

Intervention type: DRUG
Intervention: Avelumab first-line maintenance
Description: Patients with LA/mUC who following 4-6 cycles platinum chemotherapy and have not progressed, received avelumab, recommended dose of 10mg/kg body weight, intravenously administered over 60 minutes every 2 weeks
Study: NCT05648526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACTH4-10Pro8-Gly9-Pro10
Description: ACTH4-10Pro8-Gly9-Pro10 also has neuromodulator characteristics to function as a neuroprotector in inhibiting the apoptotic process. Modulation by ACTH4-10Pro8-Gly9-Pro10 will increase the levels of BDNF thereby inhibiting the process of apoptosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: negative-positive control (ketamine 40 mg/kg BW subcutaneously)
Study: NCT05946278

Intervention type: OTHER
Intervention: Sample collection for gene expression
Description: This is a cross-sectional sample collection study. Vertebral bone tissue that would otherwise be discarded is collected from patients undergoing surgery to correct a spine deformity and gene expression is measure in these tissues.
Study: NCT06124872

Intervention type: OTHER
Intervention: Survey questionnaire
Description: Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported

Intervention type: OTHER
Intervention: Survey questionnaire
Description: Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported

Intervention type: OTHER
Intervention: Survey questionnaire
Description: Household screening questionnaire Snakebite details questionnaire where a history of snakebite is reported

Intervention type: OTHER
Intervention: Key informant interview
Description: Semi-structured interview with selected key informants
Study: NCT06434376

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Conventional chemotherapy combined with personalized immune regulation diagnosis and treatment technology
Description: Blood samples were collected for MRD detection within one month (week 3) after colorectal cancer surgery, and MRD-positive patients were selected for routine chemotherapy (course of 6 months). Blood and tumor tissue samples of enrolled patients were collected, and relevant clinical data were recorded. The whole exon and expression profile of surgical tumor tissue samples were sequenced, neoantigens were analyzed, and immunomodulators were prepared. After the preparation of individualized immunomodulators, combined treatment was performed simultaneously with chemotherapy. During the treatment process, patients' response to treatment and survival were observed, and tumor load, ctDNA changes, imaging and other indicators before and after treatment were compared. To evaluate the efficacy of immunotherapy.
Study: NCT04897672

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study: NCT05280756

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based transcranial direct current stimulation (tDCS)
Description: Each participant will be asked to do ten home-based tDCS sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive active home-based tDCS (constant current intensity of 2mA) anodal-left and cathodal-right prefrontal for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham home-based transcranial direct current stimulation (tDCS)
Description: Each participant will be asked to do ten home-based sessions, one per weekday, during two weeks (Monday to Friday). Each session will be supervised remotely by a member of the research staff via HIPAA-compliant videoconference. Participants will receive sham home-based tDCS for 30 minutes per session daily for 2 weeks (Monday to Friday - 10 sessions overall) via a tDCS stimulator with headgear and 5x7 (35cm2) saline-soaked surface sponge electrodes.
Study: NCT04657419

Intervention type: OTHER
Intervention: survey
Description: Self-questionnaires will be completed by the participants :~* General health and mental health~* Fatigue~* Burn-Out~* Sleepiness~* Sleep hygiene~* Symptoms of COVID
Study: NCT05807607

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of PNS electrodes during surgery, mapping to select sites with the best effect and daily modulation.
Description: PNS electrodes are implanted in the area of peripheral nerves of the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate peripheral nerves at different sites in the stump. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SCS electrode implantation at surgery, mapping to select sites with the best effect and pain modulation
Description: SСS electrodes are implanted in the area of targeted peripheral nerves in the amputated limb. During phantom pain mapping, multichannel electrodes are used to stimulate the spinal cord at different sites. Stimulation starts at a specific site at a frequency of 1 Hz and increases by 0.1 Hz until the patient no longer feels phantom pain. Stimulation turns on sequentially at different stimulation sites; sites are selected where pain is most effectively suppressed. These sites are assigned to the patient for daily modulation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Change according to the scale of the PainDetect questionnaire
Description: This procedure uses the method of electroencephalography (EEG). EEG signals are recorded during the entire experiment. First, the patient is recorded at rest with stimulator on (PNS/SCS) with eyes open and then closed, in the stimulator off state (eyes open, then closed) in order to return the patient to the preoperative state. The stimulation is then turned back on to the original level of pain suppression. The moments of pain suppression are fixed by marking.
Study: NCT06411483

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ObeEnd Band
Description: The ObeEnd band provides electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The nonfunctional ObeEnd band does not provide electrostimulation to the PC6 acupuncture point on the wrist for 30 minutes.
Study: NCT04745767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T2 formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T1 formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T1 formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T1 formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T3 formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T4 formulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-994
Description: T5 formulation.
Study: NCT05486546

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contoura with Phorcides
Description: Participants that undergo LASIK surgery using Contoura with Phorcides Analytic Engine

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WaveLight Wavefront Optimized
Description: Participants that undergo LASIK surgery using WaveLight Wavefront Optimized
Study: NCT05212454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: capecitabine, 0.5g per pill, given 1250mg/m2 twice a day for 2 weeks of the 3-week treatment course. The total duration of treatment is 8 courses.
Study: NCT05584228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine + infliximab
Description: Combination therapy using 2-2.5 mg/kg oral azathioprine plus subcutaneous infliximab

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intestinal resection
Description: Ileocolonic or small bowel resection
Study: NCT06347653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: linperlisib combined with CHOP regimen
Description: Induction therapy: cyclophosphamide 750 mg/m2 day1, doxorubicin 40-50 mg/m2 day1, vincristine 1.4 mg/m2 (max 2 mg) day1, prednisone 100 mg day1-5, linperlisib 80mg once a day，day1-21, repeat every 21 days, for 6 cycle.~Consolidation therapy: high dose chemotherapy followed by autologous hematopoietic stem cell transplantation.~Maintenance therapy: linperlisib 80 mg day1-28, up to 12 cycles.
Study: NCT05428137

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Live bacteria strain in a form of a capsule daily for 16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Postbiotic
Description: Heat treated bacteria strain in a form of a capsule daily for 16 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo in a form of a capsule given for 16 weeks
Study: NCT05713279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: In this study, the standard treatment plan (SOC) for COVID-19 in the Department of Respiratory and Critical Care Medicine was used as the best accessible treatment, and the treatment plan principle was based on the latest national guidance document (Expert Recommendations for Clinical Treatment of Severe Novel Coronavirus Infection Caused by Omicron Variant; Diagnosis and Treatment Plan for Novel Coronavirus Infection (Trial Version 10); Diagnosis and Treatment Plan for Severe Cases of Novel Coronavirus Infection (Trial Fourth Edition)). In this study, the drug flunotinib maleate (FM) 100mg is a class of JAK inhibitors of anti-inflammatory therapy of SOC as standard clinical treatment regimen, and will be used in combination with SOC according to the judgment of the investigator.
Study: NCT05175651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genetic risk assessment
Description: A coronary artery disease (CAD) and glaucoma polygenic risk scores (PRS) will be calculated for all study participants, with participants randomized to receiving either their CAD or glaucoma PRS.
Study: NCT05119426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vi-TT
Description: Single dose of vaccine administered through a mass vaccine campaign to children between 9 months and \<16 years of age. The campaign will emulate vaccine delivery as would be administered in a local mass vaccination campaign.
Study: NCT05995639

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dry Needling
Description: Dry needling is an evidence-based therapeutic procedure used primarily in musculoskeletal rehabilitation. It involves inserting thin needles into specific trigger points in muscles, tendons, or fascia, aiming to alleviate pain and improve musculoskeletal function. Unlike acupuncture, dry needling focuses on resolving myofascial pain and dysfunction by directly targeting trigger points, often identified through palpation and anatomical understanding. Academic exploration of dry needling delves into its physiological mechanisms, clinical effectiveness, and potential integration into comprehensive treatment strategies.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ozone Injection
Description: Intramuscular ozone injection is a therapeutic intervention utilized within the context of musculoskeletal care, particularly for individuals grappling with conditions such as myofascial pain syndrome and related neuromuscular issues. This technique involves the controlled introduction of ozone gas, a chemically reactive form of oxygen, directly into targeted muscle tissue through an injection. This intramuscular administration is guided by precise anatomical knowledge and is designed to harness the potential therapeutic benefits of ozone's reactive properties.
Study: NCT06526351

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early implant placement with immediate provisional restoration
Description: Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Immediate provisional restoration will be delivered.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Early implant placement with delayed loading
Description: Implants placed following early implant placement protocol with soft tissue healing (6-8 weeks after tooth extraction). GBR procedure performed together with implant placement. Delayed loading protocol followed.
Study: NCT01002365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen administration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen administration
Study: NCT06094426

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GT316
Description: Autologous Tumor Infiltrating Lymphocyte Injection